#### **BIOMARIN PHARMACEUTICAL INC**

Form 4 June 05, 2014

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Expires:

January 31, 2005

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Estimated average burden hours per response... 0.5

**OMB APPROVAL** 

Form 4 or Form 5 obligations may continue. See Instruction

Check this box

if no longer

subject to

Section 16.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

(Finit of Type	responses)									
Davis George Eric Symbol BIOMA			. Issuer Name <b>an</b> mbol OMARIN PH C [BMRN]			·5	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)			
(Last)	(First) (I		3. Date of Earliest Transaction				Director 10% OwnerX_ Officer (give title Other (specify			
C/O BIOM. PHARMAC DIGITAL I	CEUTICAL INC.	Month/Day/Year) 5/30/2014				below)  SVP, General Counsel				
	(Street) 4. If Amendment, Date Original					6. Individual or Joint/Group Filing(Check				
NOVATO, CA 94949			iled(Month/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							y Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Data any (Month/Day/Y	Code	4. Securition(A) or Dis (Instr. 3, 4)	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct Beneficial Ownership et (I) (Instr. 4)	
Common Stock	05/30/2014	05/30/2014	G V	180	D	\$ 23.21	56,588	D		
Common Stock	06/03/2014(1)	06/03/2014	D	3,562	D	\$ 60 (2)	53,026	D		
Common Stock	06/04/2014	06/04/2014	A	11,400	A	\$ 0 (3)	64,426	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)

#### Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) Common Stock	\$ 63.1	06/04/2014		A	42,700 (4)	12/04/2014	06/03/2024	Common Stock	42,700

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Davis George Eric

C/O BIOMARIN PHARMACEUTICAL INC.

105 DIGITAL DRIVE NOVATO, CA 94949 SVP, General Counsel

## **Signatures**

/s/ Laura Randall Woodhead,

Attorney-in-Fact

06/05/2014

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pusuant to a Rule 10b5-1 trading place executed on December 11, 2013.
- (2) All shares sold at same price.
- (3) Restricted stock units granted on June 4, 2014. Price not applicable.
- (4) Option grant vests 6/4ths on December 4, 2014 and 1/48th on the 4th da of every month thereafter

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners 2

## Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.